Blog

Numinus Earnings Report Analysis— Q3 2023: Bullish Vs Bearish?

Jul 28 • 1 min read

In this episode of Bullish vs Bearish, Adam Tubero talks about Numinus Wellness ($NUMI). Here is everything you need to know about the company’s recent earnings report. Are you Bullish or Bearish? Watch the video and leave a comment.

How I Overcame My Nicotine Addiction with Magic Mushrooms

Jul 27 • 8 min read

Written by Dustin Robinson A few months ago, I decided to embark on a psychedelic journey to break free from the grip of my addiction to nicotine vaping. As an investor in several companies researching psychedelics for addiction, I am acutely aware of its incredible healing potential. Substance and behavioral addictions affect over 1.3 billion…

Treating Anorexia with Psychedelics

Jul 27 • 6 min read

The problem with treating eating disorders is that most people who have them don’t want to change. Many people struggling with psychiatric disorders are desperate for help, but those with Anorexia Nervosa believe that they are fixing themselves. In actuality, they are inflicting serious harm upon themselves. Body image issues are a huge problem, especially…

Mydecine Innovations Group Provides Corporate Update

Jul 25 • 2 min read

Mydecine Innovations Group Inc. (NEO:MYCO / OTC:MYCOF / FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that John Ross, the Company’s current Chief Financial Officer has been appointed as Corporate Secretary, effective immediately….

PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney

Jul 25 • 3 min read

PharmAla Biotech Holdings Inc. (CSE: MDMA / OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is thrilled that – following pre-submission meetings held in Q1 of 2023 – it has received written guidance from the UK’s Medicines and Healthcare products Regulatory Agency’s (MHRA). The guidance…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543